Calls
1
u/Extlis
Reddit r/pennystocks
Win Rate
100.0%
return
+0.3%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Sep 16
$0.07
+0.3%
Author took a starter position in OTC biotech RMTG, whose Cellgenics peptide division and ISSCA physician-training ecosystem are riding the post-Ozempic regenerative medicine boom. Revenue jumped from $5.1m for all of 2025 to $6.66m in H1 2026, with Q2 at $4.02m versus $984k a year earlier, driven by both product sales and physician training, while dilution stayed under 5% over the past year. The author cites debt and interest expense as the main risk and is still evaluating before taking a larger position. Chart shows higher highs and lows with accumulation in the .08 range.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Extlis has 1 trade ideas tracked on Buzzberg across 1 tickers since September 2026. Most covered: RMTG.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
